Search

Displaying results 1931 - 1940 of 4301 in total
  1. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.

  2. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

  3. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC). Odevixibat is the first approv...

  4. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783] … [A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence.

  5. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding

  6. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

  7. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

  8. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

  9. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  10. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.